A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

Stopped early

Conditions studied: Bladder Cancer, CIS

In brief

The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine practice conditions.

Key facts

Study ID

NCT01314664

Run by

Endo USA Inc., a Keenova Therapeutics Company

People needed

15

Starts

2011-05-01

Expected to finish

2012-01-01

Last updated by the study team

2015-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females 18 years of age and older
• Diagnosed with NMIBC
• Prescribed intravesical valrubicin to treat NMIBC
• Understood and signed Informed Consent to participate

You may not qualify if…

• None

Where it is running

• BCG Oncology — Phoenix, Arizona, United States
• Urology Research Network — Hialeah, Florida, United States
• Advanced Urology Association of Florida — Vero Beach, Florida, United States
• Kansas City Urology Care — Overland Park, Kansas, United States
• Delaware Valley Urology — Sewell, New Jersey, United States
• Delaware Valley Urology — Voorhees Township, New Jersey, United States
• Long Island Urological Associates — Bethpage, New York, United States
• Urologic Consultants of SE PA — Bala-Cynwyd, Pennsylvania, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Urology Associates of North Texas — Arlington, Texas, United States
• Urology Clinics of North Texas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.